Mankind Pharma Limited — Others, 23-01-2025: Statement of deviation(s) or variation(s) under Reg. 32

Mankind Pharma Limited has announced a board meeting to review and approve the financial results for the quarter and nine months ended December 31, 2024. The company's total income was reported at ₹2,466.39 crore, marking a decrease compared to the previous quarter. Profit after tax for continuing operations stood at ₹416.38 crore. Notably, the company underwent a significant strategic move, acquiring Bharat Serums and Vaccines Limited for ₹13,768 crore, which is set to enhance its market position. This update may foster positive sentiment among investors due to the growth strategy, though operational challenges persist given the drop in revenue.